Zahra Sadouki, Emmanuel Q. Wey, Sateesh Iype, David Nasralla, Jonathan Potts, Mike Spiro, Alan Williams, Timothy D. McHugh, Frank Kloprogge
{"title":"针对肝移植患者 XDR 大肠杆菌的个性化 CZA-ATM 剂量；体外中空纤维感染模型 (HFIM) 的应用","authors":"Zahra Sadouki, Emmanuel Q. Wey, Sateesh Iype, David Nasralla, Jonathan Potts, Mike Spiro, Alan Williams, Timothy D. McHugh, Frank Kloprogge","doi":"10.1101/2024.04.08.24301402","DOIUrl":null,"url":null,"abstract":"<strong>Background & aims</strong> An extensively-drug resistant (XDR) NDM and OXA-48 producing <em>E. coli</em> contributing to repeat episodes of biliary sepsis was isolated from the blood stream of a 45-55 year-old male with a background of IgG4 related sclerosing cholangitis. The patient was awaiting orthotopic liver transplant (OLT). There is no standardized antibiotic prophylaxis regimen however in line with the Infectious Diseases Society of America (IDSA) guidance an antibiotic prophylactic regimen of Ceftazidime-Avibactam (CZA) 2.5g TDS with Aztreonam (ATM) 2g TDS IV was proposed.","PeriodicalId":501447,"journal":{"name":"medRxiv - Pharmacology and Therapeutics","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Personalized CZA-ATM dosing against an XDR E. coli in liver transplant patients; the application of the in vitro hollow fibre infection model (HFIM)\",\"authors\":\"Zahra Sadouki, Emmanuel Q. Wey, Sateesh Iype, David Nasralla, Jonathan Potts, Mike Spiro, Alan Williams, Timothy D. McHugh, Frank Kloprogge\",\"doi\":\"10.1101/2024.04.08.24301402\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>Background & aims</strong> An extensively-drug resistant (XDR) NDM and OXA-48 producing <em>E. coli</em> contributing to repeat episodes of biliary sepsis was isolated from the blood stream of a 45-55 year-old male with a background of IgG4 related sclerosing cholangitis. The patient was awaiting orthotopic liver transplant (OLT). There is no standardized antibiotic prophylaxis regimen however in line with the Infectious Diseases Society of America (IDSA) guidance an antibiotic prophylactic regimen of Ceftazidime-Avibactam (CZA) 2.5g TDS with Aztreonam (ATM) 2g TDS IV was proposed.\",\"PeriodicalId\":501447,\"journal\":{\"name\":\"medRxiv - Pharmacology and Therapeutics\",\"volume\":\"4 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Pharmacology and Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.04.08.24301402\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.04.08.24301402","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Personalized CZA-ATM dosing against an XDR E. coli in liver transplant patients; the application of the in vitro hollow fibre infection model (HFIM)
Background & aims An extensively-drug resistant (XDR) NDM and OXA-48 producing E. coli contributing to repeat episodes of biliary sepsis was isolated from the blood stream of a 45-55 year-old male with a background of IgG4 related sclerosing cholangitis. The patient was awaiting orthotopic liver transplant (OLT). There is no standardized antibiotic prophylaxis regimen however in line with the Infectious Diseases Society of America (IDSA) guidance an antibiotic prophylactic regimen of Ceftazidime-Avibactam (CZA) 2.5g TDS with Aztreonam (ATM) 2g TDS IV was proposed.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
